Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SHLT
Upturn stock ratingUpturn stock rating

SHL Telemedicine Ltd American Depositary Shares (SHLT)

Upturn stock ratingUpturn stock rating
$2.05
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: SHLT (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $11

1 Year Target Price $11

Analysts Price Target For last 52 week
$11Target price
Low$1.85
Current$2.05
high$5.09

Analysis of Past Performance

Type Stock
Historic Profit -5.4%
Avg. Invested days 32
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 39.26M USD
Price to earnings Ratio -
1Y Target Price 11
Price to earnings Ratio -
1Y Target Price 11
Volume (30-day avg) 1
Beta 0.29
52 Weeks Range 1.85 - 5.09
Updated Date 06/30/2025
52 Weeks Range 1.85 - 5.09
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.53

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -15.8%
Operating Margin (TTM) -14.07%

Management Effectiveness

Return on Assets (TTM) -4.07%
Return on Equity (TTM) -11.51%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 38497073
Price to Sales(TTM) 0.7
Enterprise Value 38497073
Price to Sales(TTM) 0.7
Enterprise Value to Revenue 0.68
Enterprise Value to EBITDA 16.11
Shares Outstanding 16391400
Shares Floating 10360993
Shares Outstanding 16391400
Shares Floating 10360993
Percent Insiders -
Percent Institutions 21.8

Analyst Ratings

Rating 1
Target Price 11
Buy -
Strong Buy 1
Buy -
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

SHL Telemedicine Ltd American Depositary Shares

stock logo

Company Overview

overview logo History and Background

SHL Telemedicine Ltd. (American Depositary Shares) was founded in 1987. It is a global provider of telemedicine solutions, focusing on remote cardiac monitoring and other remote patient care services. They have evolved from initially providing emergency response services to offering comprehensive telemedicine platforms.

business area logo Core Business Areas

  • Telecardiology: Remote cardiac monitoring services, including ECG transmission and analysis.
  • Remote Patient Monitoring (RPM): Platforms and services for remotely monitoring patients with chronic conditions like heart failure and diabetes.
  • Personal Emergency Response Systems (PERS): Solutions that allow elderly or disabled individuals to call for help in case of an emergency.

leadership logo Leadership and Structure

Key leaders include the CEO and CFO. The organizational structure is likely a mix of functional departments (e.g., R&D, Sales, Marketing) and business units (e.g., Telecardiology, RPM).

Top Products and Market Share

overview logo Key Offerings

  • MOMO Cardiac Monitoring System: A system for real-time ECG monitoring and analysis. Market share data is difficult to pinpoint precisely, but key competitors include companies like iRhythm Technologies (IRTC), BioTelemetry (part of Philips), and Preventice Solutions (part of Boston Scientific).
  • RPM Platform: A platform for remotely monitoring patients with chronic conditions. Market share is fragmented. Competitors include Teladoc Health (TDOC), Amwell (AMWL), and many smaller telehealth providers.

Market Dynamics

industry overview logo Industry Overview

The telemedicine industry is experiencing rapid growth, driven by factors like aging populations, increasing chronic disease prevalence, and technological advancements.

Positioning

SHL Telemedicine is positioned as a provider of comprehensive telemedicine solutions, with a strong focus on cardiac monitoring. Their competitive advantages include their expertise in telecardiology and their established presence in certain markets.

Total Addressable Market (TAM)

The global telemedicine market is expected to reach hundreds of billions of USD. SHL Telemedicine is positioned to capture a share of this market through its specialized services.

Upturn SWOT Analysis

Strengths

  • Established presence in the telecardiology market
  • Comprehensive telemedicine platform
  • Strong technology expertise
  • Experienced management team

Weaknesses

  • Smaller size compared to larger telehealth companies
  • Limited brand recognition in some markets
  • Dependence on reimbursement policies

Opportunities

  • Expanding into new geographic markets
  • Developing new telemedicine solutions
  • Acquiring smaller telehealth companies
  • Partnering with healthcare providers

Threats

  • Increasing competition from larger telehealth companies
  • Changes in reimbursement policies
  • Technological obsolescence
  • Data security breaches

Competitors and Market Share

competitor logo Key Competitors

  • TDOC
  • AMWL
  • IRTC

Competitive Landscape

SHL Telemedicine faces intense competition from larger, more established telehealth companies. Their ability to compete depends on their expertise in specific areas like telecardiology, their ability to innovate, and their effectiveness in marketing their solutions.

Major Acquisitions

CCM

  • Year: 2020
  • Acquisition Price (USD millions): 7.1
  • Strategic Rationale: To expand its remote patient monitoring capabilities in the US market.

Growth Trajectory and Initiatives

Historical Growth: Growth trends are available in parent SHL Telemedicine Ltd.'s financial reports.

Future Projections: Future growth projections are typically based on analyst estimates. Consider using available financial data to analyze potential growth.

Recent Initiatives: Recent initiatives include expanding their RPM platform and developing new telemedicine solutions.

Summary

SHL Telemedicine holds a niche position in the telemedicine market, particularly in telecardiology. While it faces competition from larger players, its specialized expertise offers a competitive edge. The company needs to strategically expand its market presence and leverage technological advancements to drive future growth. Its reliance on reimbursement policies presents an ongoing risk to financial performance.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings (SHL Telemedicine Ltd.)
  • Market Research Reports (Telemedicine Industry)
  • Financial News Outlets

Disclaimers:

The data provided is for informational purposes only and should not be considered financial advice. Market share estimates are based on publicly available data and may not be precise. Always consult with a qualified financial advisor before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About SHL Telemedicine Ltd American Depositary Shares

Exchange NASDAQ
Headquaters -
IPO Launch date 2023-04-03
CEO -
Sector Healthcare
Industry Health Information Services
Full time employees 583
Full time employees 583

SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. It offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; and Cardio'B, a portable device to transmit a 12-lead ECG. The company also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices, including blood pressure, weighing, oxygen saturation level (TelePulse Oximeter), breath exhalation (TeleBreather), and sugar measuring devices; and TelePress, a remote blood pressure monitoring device for personal use. It offers its telemedicine services and devices to subscribers using electronic and telecommunication technologies. The company serves physicians, hospitals, health insurance funds, and patients. It has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and the Hebrew University of Jerusalem and the Hadassah Medical Center. The company was incorporated in 1986 and is headquartered in Tel Aviv, Israel.